Jordonna Brown
Hematology & Oncology · Brooklyn, NYNPI 1467985564
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,166 of the $1,747 with a category attached, or 66.7%. It is spread thinly across 23 manufacturers, the largest accounting for just 15.1%. Reporting peaked in 2024 at $851 and has fallen 76.3% since, to $201 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 58 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$263
- Novartis$257
- Astellas Pharma US Inc$231
- Seagen Inc.$169
- Johnson & Johnson$119
- Amgen$115
- plus $592 from 17 others
What the payments were for
- Food & beverage$1,16667%
- Education$58133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 9 | $263 |
| Novartis | 11 | $257 |
| Astellas Pharma US Inc | 4 | $231 |
| Seagen Inc. | 4 | $169 |
| Johnson & Johnson | 5 | $119 |
| Amgen | 2 | $115 |
| Incyte Corporation | 2 | $109 |
| Taiho Oncology, Inc. | 5 | $105 |
| Lilly USA, LLC | 2 | $47 |
| Sanofi | 1 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Merck | 1 | $28 |
| Bayer | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| CSL Behring | 1 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Pfizer | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| GSK | 1 | $14 |
How this compares
$1,747 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 11 | $107,718 |
| Hydroxyurea | 19 | $445 |
| Anastrozole | 36 | $443 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Brooklyn
- Perry CookBrooklyn$803K
- Ilya BlokhBrooklyn$220K
- Yiwu HuangBrooklyn$220K
- Songchuan GuoBrooklyn$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.